Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning... Show more
AIFF is the stock ticker for Firefly Neuroscience, Inc., a technology company headquartered in Kenmore, New York. Firefly operates at the intersection of artificial intelligence and neuroscience, developing medical devices and software that help clinicians visualize and evaluate how different regions of the human brain communicate. Investors follow the company because it represents a bet on the convergence of AI and precision medicine, two long-term technology themes, within the specialized field of brain health.
Firefly Neuroscience describes itself as an artificial intelligence company advancing precision neuroscience. The company develops, markets, and distributes technologies for the high-resolution visualization and evaluation of the brain's neurophysiological interconnections, primarily serving clinicians across North America.
Its core technology is the Brain Network Analytics (BNA™) platform, which has received FDA 510(k) clearance. The platform works in conjunction with the Evoke System, a device used to perform electroencephalography (EEG) — the measurement of the brain's electrical activity — and event-related potential (ERP) assessments, which record how the brain responds to specific stimuli. These assessments are analyzed by Firefly's cloud-based software and returned as structured reports designed to support clinical decision-making for conditions including depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), dementia, Parkinson's disease, bipolar disorder, schizophrenia, and traumatic brain injury.
According to SEC filings, the company was founded in 2006 and is based at 1100 Military Road in Kenmore, New York. Firefly began trading on the Nasdaq Capital Market under the ticker AIFF on August 13, 2024, and its corporate structure includes subsidiaries such as Evoke Neuroscience, Inc., which it acquired in May 2025. The acquisition expanded Firefly's proprietary brain-scan database, patent portfolio, and commercial footprint.
Financially, Firefly is a small, early-stage company. It reports modest annual revenue and a workforce of roughly 17 employees, and it has generated net losses as it invests in commercialization and research. Its business model centers on selling and deploying its assessment technology to clinicians, while also targeting pharmaceutical companies conducting drug research and clinical trials, where objective brain-function data can support trial design and treatment evaluation.
Firefly attracts investor attention primarily for its positioning at the convergence of artificial intelligence and brain health. A key strategic asset is its proprietary database of standardized EEG/ERP brain scans, which the company describes as among the largest known of its kind. Management has stated its ambition to use this dataset, combined with advanced computing resources such as NVIDIA's GPU acceleration, to build a foundation model of the human brain — an AI system trained on large-scale brain-activity data that could support biomarker discovery and more personalized diagnosis.
The company's FDA clearance is another notable differentiator, providing regulatory validation that many early-stage AI-healthcare startups do not yet have. Firefly has also pursued commercial partnerships to expand the reach of its technology, including collaborations aimed at introducing its Evoke platform into broader clinical networks and integrating it with other brain-health systems. For investors interested in the long-term theme of AI-enabled diagnostics, these elements give Firefly a distinct market position relative to traditional medical device or software firms.
Investing in AIFF involves meaningful risks. The company is early-stage, with limited revenue and recurring net losses, and it may require additional capital to fund operations and growth. Its small employee base and relatively young commercial footprint mean execution risk is high, and future dilution from equity financings is a common consideration for companies of this size.
The broader market for brain-assessment technologies is competitive and still developing, and adoption of Firefly's products depends on clinician acceptance, reimbursement dynamics, and regulatory requirements. As a micro-cap stock, AIFF can also experience pronounced price volatility and lower trading liquidity than larger companies. Investors should carefully evaluate the company's financial profile, commercialization progress, and competitive landscape before making decisions.
For investors seeking to discover opportunities like AIFF, Tickeron's AI Screener is an AI-powered stock and ETF discovery platform. It helps traders and investors filter thousands of securities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, and price patterns. Users can customize their own criteria to efficiently find ideas that align with their individual investment strategies. Explore the AI Screener to build your own watchlists and uncover candidates across sectors.
Firefly Neuroscience is an early-stage company seeking to translate artificial intelligence and large-scale brain data into clinically useful tools for diagnosing and monitoring neurological and mental health conditions. Its FDA-cleared BNA platform, proprietary EEG/ERP database, and stated goal of building a foundation model of the human brain distinguish it within the emerging AI-healthcare space. At the same time, its limited revenue, ongoing losses, and early commercialization stage mean investors should weigh its long-term potential against a higher-risk financial profile.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PackagedSoftware